A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).

doi:10.1200/JCO.2021.39.15_suppl.2039

	A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).
	Li, Peijing ; Chen, Yuan Yuan Yuan ; Lai, Shuzhen ; Jiang, Fagui ; Liu, Xiaohui ; Tao, Changjuan ; Wang, Lei ; Liu, Guihong ; Huang, Jing ; Tang, Yiqiang
刊名	JOURNAL OF CLINICAL ONCOLOGY
	2021-05-20
卷号	39
ISSN号	0732-183X
DOI	10.1200/JCO.2021.39.15_suppl.2039
WOS研究方向	Oncology
语种	英语
出版者	LIPPINCOTT WILLIAMS & WILKINS
WOS记录号	WOS:000708120600324
内容类型	期刊论文
源URL	[http://ir.hfcas.ac.cn:8080/handle/334002/126698]
专题	中国科学院合肥物质科学研究院
作者单位	1.Sun Yat Sen Univ, Affiliated Hosp 1, Guangzhou, Peoples R China 2.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 3.Shantou Univ, Guangdong YueBei Peoples Hosp, Shaoguan, Peoples R China 4.Kecheng Dist Peoples Hosp, Quzhou, Peoples R China 5.Univ Chinese Acad Sci, Zhejiang Canc Hosp, Canc Hosp, Hangzhou, Peoples R China 6.Xuzhou Med Univ, Affiliated Hosp, Xuzhou, Jiangsu, Peoples R China 7.Nanjing Med Univ, Huaian Hosp 1, Huaian, Peoples R China 8.Nanchang Univ, Canc Hosp, Nanchang, Jiangxi, Peoples R China 9.Sun Yat Sen Univ, Affiliated Hosp 5, Zhuhai, Peoples R China 10.Maoming Peoples Hosp, Maoming, Peoples R China
推荐引用方式 GB/T 7714	Li, Peijing,Chen, Yuan Yuan Yuan,Lai, Shuzhen,et al. A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).[J]. JOURNAL OF CLINICAL ONCOLOGY,2021,39.
APA	Li, Peijing.,Chen, Yuan Yuan Yuan.,Lai, Shuzhen.,Jiang, Fagui.,Liu, Xiaohui.,...&Lu, Fangxiao.(2021).A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM)..JOURNAL OF CLINICAL ONCOLOGY,39.
MLA	Li, Peijing,et al."A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).".JOURNAL OF CLINICAL ONCOLOGY 39(2021).